Our Capital Markets team advised Jefferies, Evercore, Bryan Garnier & Co and Truist on Medincell’s capital increase for a total amount of c. €43 million through an offering to institutional investors via a private placement and a public offering to retail investors via the PrimaryBid platform only in France.
Medincell is a French commercial stage pharmaceutical technology company developing a portfolio of long-acting injectable products in various therapeutic areas.
This fundraising will enable Medincell to expand BEPO® technology into new molecules and high value indications, and potentially integrate complementary technologies.
The Goodwin team was led by Guilhem Richard on French law aspects and Ben Marsh on US law aspects, and included Mariléna Gryparis and Shanna Kim.